Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

JP Morgan Cuts Celgene Rating


JP Morgan downgraded Celgene Corp. (CELG) to long-term buy from buy.

Analyst Franklin Berger says the downgrade is based on a 9-12 month delay in Celgene's Total Therapy II trial for multiple myeloma. He adds that Phase III interim data still isn't available, as he had forecast. Berger says the company plans to file its Thalomid NDA in Q3 2001; in his opinion, the regulatory risk now is higher without positive 2TII trial results.

He cut the $87.5 million 2001 Thalomid sales estimate to $76.5 million and cut the $0.32 2001 EPS estimate to $0.27.


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus